Skip to content

It looks like we may have content for your preferred language. Would you like to view this page in English?

FDA's Lack Of Power May Limit FTC's Patent Challenge

Loeb & Loeb Food and Drug Administration partner Jim Czaban, was quoted in Law360 discussing how the Federal Trade Commission's (FTC) is challenging over 100 pharmaceutical patents, with a specific focus on concerns related to drug pricing. The FTC has notified the U.S. Food and Drug Administration (FDA) regarding potential inaccuracies in patent listings by major drugmakers, which could artificially extend their exclusivity and delay generic competition.

In a comment to the publication, Jim discusses the warnings against abuse of patent listings, "The FTC doesn't let go of these issues lightly, they're just going to keep coming back to it until something is resolved."
To read the full article, visit Law360’s website.